Clinical application of biologic agents in managing moderate-to-severe asthmas while advancing the rate of patient referrals to specialists and asthma specialty clinics
FACULTY
Nicola Hanania, MD, MS
Director, Airways Clinical Research Center
Professor of Medicine
Clinical Science Representative
Faculty Senate, Baylor College of Medicine
Chief, Section of Pulmonary and Critical Care Medicine
Ben Taub Hospital
Houston, TX
PROGRAM OVERVIEW
These podcasts are designed to assist members of the multidisciplinary respiratory care team in identifying approaches to improve patient care for those with moderate-to-severe asthma. Reducing the reliance on oral corticosteroids through the use of targeted biologic agents will be discussed. Additionally, the risks associated with even short courses of low-dose prednisone will be reviewed. This program features expert analysis of the latest clinical trial outcomes of biologic therapies, as well as guidance on when referral to a specialist is appropriate.
TARGET AUDIENCE
This activity is designed to meet the educational needs of community primary care clinicians, allergists, immunologists, pulmonologists, otolaryngologists (ENT specialists), and other members of the multidisciplinary team to ensure an up-to-date understanding of the latest data in management of moderate-to-severe asthma.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Discuss the clinical evidence for approved and investigational biologics for the treatment of moderate-to-severe asthma
- Detail strategies to improve appropriate referrals to implement multidisciplinary care effectively
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.33 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.33 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Nicola Hanania, MD | Discloses that he has received consulting fees from GlaxoSmithKline, AstraZeneca, Regeneron, Sanofi, Genentech, Boehringer Ingelheim, Verona Pharmaceuticals. He has participated in Speakers’ Bureaus for Sanofi and Regeneron. In addition, he has conducted contracted research for Sanofi, Genentech, GlaxoSmithKline and AstraZeneca. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Dominque Barton, RN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Dave Chatman, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Ana Maria Albino, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Jessica Feygin-Samuels, Associate Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected].
Please listen to the podcast below:
RELEASED DATE: March 28, 2024
EXPIRATION DATE: March 28, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
Strategies to minimize the use of oral corticosteroids in addition to the clinical application of biologic agents in managing moderate-to-severe asthma
FACULTY
Anju T. Peters, MD, MSCI
Associate Chief of Clinical Practice and Innovation
Division of Allergy and Immunology
Director, Center for Clinical Research
Northwestern University Clinical and Translational Sciences Institute (NUCATS)
Chicago, IL
PROGRAM OVERVIEW
These podcasts are designed to assist members of the multidisciplinary respiratory care team in identifying approaches to improve patient care for those with moderate-to-severe asthma. Reducing the reliance on oral corticosteroids through the use of targeted biologic agents will be discussed. Additionally, the risks associated with even short courses of low-dose prednisone will be reviewed. This program features expert analysis of the latest clinical trial outcomes of biologic therapies, as well as guidance on when referral to a specialist is appropriate.
TARGET AUDIENCE
This activity is designed to meet the educational needs of community primary care clinicians, allergists, immunologists, pulmonologists, otolaryngologists (ENT specialists), and other members of the multidisciplinary team to ensure an up-to-date understanding of the latest data in management of moderate-to-severe asthma.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Explain the burden chronic OCS usage imparts on achieving treatment goals, daily QoL, and associated toxicities in managing asthma
- Discuss the clinical evidence for approved and investigational biologics for the treatment of moderate-to-severe asthma
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.33 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.33 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Anju T. Peters, MD | Discloses that she has received consulting fees from Sanofi, Regeneron Pharmaceuticals, Inc., AstraZeneca, Merck, GlaxoSmithKline and Chiesi. She has conducted contracted research for Sanofi, Regeneron Pharmaceuticals, Inc., AstraZeneca and Merck. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Dominque Barton, RN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Dave Chatman, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Ana Maria Albino, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Jessica Feygin-Samuels, Associate Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected].
Please listen to the podcast below:
RELEASED DATE: March 28, 2024
EXPIRATION DATE: March 28, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
A patient’s viewpoint in the treatment of moderate-to-severe asthma
PATIENT
Dr. Barton Slatko
Houston, TX
PROGRAM OVERVIEW
These podcasts are designed to assist members of the multidisciplinary respiratory care team in identifying approaches to improve patient care for those with moderate-to-severe asthma. Reducing the reliance on oral corticosteroids through the use of targeted biologic agents will be discussed. Additionally, the risks associated with even short courses of low-dose prednisone will be reviewed. This program features expert analysis of the latest clinical trial outcomes of biologic therapies, as well as guidance on when referral to a specialist is appropriate.
TARGET AUDIENCE
This activity is designed to meet the educational needs of community primary care clinicians, allergists, immunologists, pulmonologists, otolaryngologists (ENT specialists), and other members of the multidisciplinary team to ensure an up-to-date understanding of the latest data in management of moderate-to-severe asthma.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Explain the burden chronic OCS usage imparts on achieving treatment goals, daily QoL, and associated toxicities in managing asthma
- Discuss the clinical evidence for approved and investigational biologics for the treatment of moderate-to-severe asthma
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.33 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.33 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Patient | Disclosures |
| Barton Slatko, PhD | Has nothing to disclose. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Dominque Barton, RN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Dave Chatman, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Ana Maria Albino, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Jessica Feygin-Samuels, Associate Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected].
Please listen to the podcast below:
RELEASED DATE: March 28, 2024
EXPIRATION DATE: March 28, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
